Adaptive Biotechnologies Corporation (ADPT)
Stock Price:
$49.50 USD
2.57 (5.48%)
Updated Oct 23, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
6.72B |
| Revenue (ttm) |
92.17M |
| Net Income (ttm) |
-99.50M |
| Shares Out |
135.79M |
| EPS (ttm) |
-0.79 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 23, 2020 |
| Last Price |
$49.50 |
| Previous Close |
$46.93 |
| Change ($) |
2.57 |
| Change (%) |
5.48% |
| Day's Open |
47.35 |
| Day's Range |
47.27 - 49.68 |
| Day's Volume |
655,392 |
| 52-Week Range |
15.19 - 54.20 |
More Stats
| Market Cap |
6.72B |
| Enterprise Value |
6.20B |
| Earnings Date (est) |
Nov 10, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
135.79M |
| Float |
130.33M |
| EPS (basic) |
-0.66 |
| EPS (diluted) |
-0.79 |
| FCF / Share |
-1.03 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
5.22M |
| Short Ratio |
4.60 |
| Short % of Float |
4.00% |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
72.93 |
| PB Ratio |
12.03 |
| Revenue |
92.17M |
| Operating Income |
-113.77M |
| Net Income |
-99.50M |
| Free Cash Flow |
-130.68M |
| Net Cash |
526.79M |
| Net Cash / Share |
3.88 |
| Gross Margin |
-8.58% |
| Operating Margin |
-123.44% |
| Profit Margin |
-108.00% |
| FCF Margin |
-141.79% |
| ROA |
-9.77% |
| ROE |
-24.57% |
| ROIC |
-19.30% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (8)
| Buy |
7 |
| Overweight |
0 |
| Hold |
1 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$54.50*
(10.10% upside)
Low
42.0
Current: $49.50
High
63.0
Target: 54.50
*Average 12-month price target from 6 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 |
|---|
| Revenue | 85.07 | 55.66 | 38.45 |
| Revenue Growth | 52.83% | 44.77% | - |
| Gross Profit | 62.80 | 36.00 | 22.77 |
| Operating Income | -78.39 | -49.76 | -44.48 |
| Net Income | -68.61 | -46.45 | -42.83 |
| Shares Outstanding | 69.17 | 12.63 | 12.20 |
| Earnings Per Share | -1.01 | -3.67 | -3.50 |
| Operating Cash Flow | 205 | -32.26 | -34.86 |
| Capital Expenditures | -11.20 | -6.30 | -2.21 |
| Free Cash Flow | 194 | -38.56 | -37.07 |
| Cash & Equivalents | 579 | 165 | 192 |
| Total Debt | 36.61 | - | - |
| Net Cash / Debt | 542 | 165 | 192 |
| Assets | 912 | 333 | 362 |
| Liabilities | 341 | 29.94 | 25.77 |
| Book Value | 571 | -258 | -225 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Adaptive Biotechnologies Corporation |
| Country |
United States |
| Employees |
453 |
| CEO |
Chad Robins |
Stock Information
| Ticker Symbol |
ADPT |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: ADPT |
| IPO Date |
June 27, 2019 |
Description
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ research service and kit that is used to answer research questions, as well as to discover new prognostic and diagnostic signals. It also provides clonoSEQ diagnostic tests, which include immunosequencing services for use in the detection and monitoring of minimal residual disease in patients with select blood cancers. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test; and Amgen to develop a therapeutic to prevent or treat COVID-19. It serves the life sciences research, clinical diagnostics, and drug discovery customers. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was founded in 2009 and is headquartered in Seattle, Washington.